This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2020
  • /
  • 09
  • /
  • Phase III CheckMate-577 trial of Opdivo shows bene...

Phase III CheckMate-577 trial of Opdivo shows benefits in oesophageal cancer.- BMS

Read time: 1 mins
Published:23rd Sep 2020
Bristol Myers Squibb announced that checkpoint inhibitor treatment Opdivo (nivolumab) demonstrated its efficacy in the phase III CheckMate-577 trial involving patients with oesophageal or gastroesophageal junction cancers who had previously received neoadjuvant chemoradiation therapy and tumour resection. The results showed that median disease-free survival doubled in patients receiving Opdivo treatment versus those patients receiving placebo after surgery. The median duration of treatment for patients in the Opdivo arm was 10.1 months compared to 9 months in the placebo arm. The treatment was also well tolerated, with an acceptable safety profile versus placebo. BMS intendeds to discuss the results from the CheckMate-577 study with health authorities. Data were presented at the 2020 European Society for Medical Oncology virtual congress.
Condition: Oesophageal Cancer
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.